Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Overview | Financials
Company Name | Vanda Pharmaceuticals Inc. |
Symbol | VNDA |
Currency | USD |
Price | 4.66 |
Market Cap | 271,630,468 |
Dividend Yield | 0% |
52-week-range | 3.3 - 6.75 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mihael H. Polymeropoulos M.D. |
Website | https://www.vandapharma.com |
An error occurred while fetching data.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD